SynthesisFrontiers in pharmacology2025
Cannabis and cannabinoids in dermatology: a systematic review and meta-analysis of quantitative outcomes.
Synthesis in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- CBD-Containing Hemp Extracts and Isolated CBD for Acne: A Systematic Review of Anti-Inflammatory Mechanisms, Clinical Signals and Sustainability.Molecules (Basel, Switzerland) · 2026Pooled it
- Drug-induced psoriasis secondary to cannabis use.JAAD case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Cannabinoids, present in Design: Systematic review and meta-analysis. Data sources: PubMed, Embase, Scopus, Web of Science, and CENTRAL from inception to 30 June 2024. Eligibility criteria for selecting studies: We included randomized controlled trials and observational studies that evaluated the efficacy or effectiveness of medical cannabis or cannabinoid-based interventions in managing dermatologic conditions, regardless of the comparator type. Data extraction and synthesis: Two reviewers independently extracted data and assessed risk of bias. Outcomes were categorized into subjective outcomes, objective outcomes, and disease-specific composite scores. Meta-analyses used standard mean differences (SMDs) with 95% confidence intervals (CIs). Study quality was assessed using RoB 2 and ROBINS-I tools. Results: We included 3,359 participants from eleven randomized controlled trials, three quasi-experimental studies, and three observational studies. Interventions included topical formulations of cannabis extract ointment, cannabidiol, N-acylethanolamine (PEA), alkylamides, and HU-210. A statistically significant reduction in pruritus was observed among participants treated with cannabinoids (SMD = -0.29, 95% CI: -0.52 to -0.06, I Conclusion: Cannabinoids produced a modest but statistically significant reduction in pruritus, suggesting clinical relevance for symptom management. However, no significant benefits were observed for other dermatologic outcomes. Larger, standardized randomized trials are needed to clarify their therapeutic potential in dermatology. Systematic Review Registration: identifier CRD42023397189.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.